TICE BCG Global Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The TICE BCG market research report is one of a series of new reports that provides TICE BCG market statistics, including the TICE BCG industry global market size, regional shares, competitors with the TICE BCG market share, detailed TICE BCG market segments, market trends, and opportunities, and any further data you may need to thrive in the TICE BCG industry. This TICE BCG market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The growth in the forecast period can be attributed to the growing incidence of bladder cancer, rising prevalence of smoking, adoption of immunotherapy, rising awareness of early diagnosis, and growing focus on personalized medicine. Major trends in the forecast period include integration with diagnostic advancements, advances in surgical techniques and technologies, technological innovations in drug delivery systems, integration of combination therapies, and advancements in diagnostic techniques.

The rising incidence of bladder cancer is expected to drive the growth of the TICE BCG market. Bladder cancer, primarily urothelial carcinoma, originates in the cells of the bladder, an organ responsible for storing urine. The increase in bladder cancer cases is linked to factors such as higher smoking rates, exposure to toxic chemicals in certain industries, aging populations, and chronic bladder infections. TICE BCG works by stimulating the immune system to target and destroy cancer cells, effectively reducing the recurrence and progression of non-muscle invasive bladder cancer. According to the American Cancer Society, an estimated 83,190 new cases of urinary bladder cancer are expected in 2024, marking an increase from 82,290 in 2023. This growing incidence is driving the demand for TICE BCG.

The rise in healthcare expenditure is also expected to contribute to the growth of the TICE BCG market. Healthcare expenditure includes all spending on medical services, treatments, and public health programs, whether funded by governments, private entities, insurance, or out-of-pocket payments. Factors such as an aging population, rising chronic disease prevalence, advancements in medical technology, and increasing healthcare costs are contributing to higher healthcare spending. This surge in expenditure helps improve access to specialized treatments and boosts funding for therapies such as TICE BCG. For instance, UK healthcare expenditure reached approximately $354.88 billion in 2022, reflecting a 0.7% increase from the previous year, according to the Office for National Statistics. As a result, the rise in healthcare spending is positively impacting the TICE BCG market.

The growing adoption of personalized medicine is another factor expected to drive the growth of the TICE BCG market. Personalized medicine involves creating tailored treatment plans that consider a patient's individual genetic makeup, lifestyle, environment, and health history. The increasing adoption of this approach is fueled by advances in genomics, biotechnology, and diagnostics, along with better treatment outcomes and patient demand. Personalized medicine enhances the effectiveness of treatments such as TICE BCG by customizing care to suit individual disease characteristics. In 2023, the FDA approved 16 new personalized treatments for rare diseases, a significant increase from the six approvals in 2022, according to the Personalized Medicine Coalition. This growing shift towards personalized healthcare is contributing to the growth of the TICE BCG market.

The key company operating in the TICE BCG market is Merck And Co Inc.

North America was the largest region in the TICE BCG market in 2024. The regions covered in TICE BCG report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the TICE BCG market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

TICE BCG is an intravesical therapy used to treat non-muscle invasive bladder cancer (NMIBC) by stimulating the immune system to target and eliminate cancer cells. It is mainly administered after tumor resection to help reduce the risk of recurrence and progression, particularly in high-risk NMIBC patients.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

TICE BCG is indicated for the treatment of both tuberculosis and bladder cancer. Tuberculosis is a contagious infection caused by Mycobacterium tuberculosis, primarily affecting the lungs but capable of spreading to other areas of the body. The medication is available in different forms, including freeze-dried preparations and liquid suspensions, and is distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies. It is used by a range of end users, including hospitals, clinics, research laboratories, and specialized cancer centers.

The TICE BCG market consists of sales of intravesical therapy kits, injections, powders for reconstitution, intravesical suspensions, and lyophilized powders. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.